Identifying Mixed Phenotype: Evaluating the Presence of Polyneuropathy in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Cardiomyopathy

被引：0
|
作者：
Merkel, Madeline [1 ]
Grogan, Martha [2 ]
Hawkins, Philip N. [3 ]
Kristen, Arnt V. [4 ]
Berk, John L. [5 ]
Suhr, Ole B. [6 ]
Lin, Hollis [1 ]
McManus, Anastasia [1 ]
Powell, Christine [1 ]
Vest, John [1 ]
Karsten, Verena [1 ]
Judge, Daniel P. [7 ]
机构：
[1] Alnylam Pharmaceut, Cambridge, MA USA
[2] Mayo Clin, Rochester, MN USA
[3] Royal Free Hosp, NAC, London, England
[4] Heidelberg Univ Hosp, Heidelberg, Germany
[5] Boston Univ, Boston, MA 02215 USA
[6] Umea Univ, Umea, Sweden
[7] Med Univ South Carolina, Columbia, SC USA
来源：
NEUROLOGY | 2020年 / 94卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
240
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR)
    Judge, Daniel P.
    Kristen, Arnt V.
    Grogan, Martha
    Maurer, Mathew S.
    Falk, Rodney H.
    Hanna, Mazen
    Gillmore, Julian
    Garg, Pushkal
    Vaishnaw, Akshay K.
    Harrop, Jamie
    Powell, Christine
    Karsten, Verena
    Zhang, Xiaoping
    Sweetser, Marianne T.
    Vest, John
    Hawkins, Philip N.
    CARDIOVASCULAR DRUGS AND THERAPY, 2020, 34 (03) : 357 - 370
  • [32] The V122I Mutation in Hereditary Transthyretin-Mediated Amyloidosis is Significantly Associated with Polyneuropathy
    Nioi, Paul
    Parker, Meg M.
    Damrauer, Scott M.
    Rader, Daniel J.
    Ticau, Simina
    Erbe, David
    Hinkle, Greg
    NEUROLOGY, 2020, 94 (15)
  • [33] The V122I Mutation in Hereditary Transthyretin-Mediated Amyloidosis is Significantly Associated with Polyneuropathy
    Parker, Margaret M.
    Damrauer, Scott M.
    Rader, Daniel J.
    Ticau, Simina
    Erbe, David
    Hinkle, Gregory
    Nioi, Paul
    JOURNAL OF CARDIAC FAILURE, 2019, 25 (08) : S110 - S110
  • [34] Indirect treatment comparison (ITC) of the efficacy of vutrisiran and tafamidis for hereditary transthyretin-mediated amyloidosis with polyneuropathy
    Merkel, Madeline
    Danese, David
    Chen, Chongshu
    Wang, Jessie
    Wu, Aozhou
    Yang, Hongbo
    Lin, Hollis
    EXPERT OPINION ON PHARMACOTHERAPY, 2023, 24 (10) : 1205 - 1214
  • [35] The V122I Variant in Hereditary Transthyretin-Mediated Amyloidosis is Significantly Associated with Polyneuropathy
    Parker, Margaret M.
    Damrauer, Scott M.
    Tcheandjieu, Catherine
    Erbe, David
    Aldinc, Emre
    Hawkins, Philip N.
    Gillmore, Julian
    Hull, Leland E.
    Lynch, Julie A.
    Joseph, Jacob
    Ticau, Simina
    Flynn-Carroll, Alexander O.
    Deaton, Aimee M.
    Ward, Lucas D.
    Assimes, Themistocles L.
    Tsao, Philip S.
    Chang, Kyong-Mi
    Rader, Daniel J.
    Fitzgerald, Kevin
    Vaishnaw, Akshay K.
    Hinkle, Gregory
    Nioi, Paul
    JOURNAL OF CARDIAC FAILURE, 2020, 26 (10) : S96 - S96
  • [36] Effect of RNAi therapeutics patisiran and vutrisiran on orthostatic hypotension due to dysautonomia in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy
    Slama, M.
    Obici, L.
    Okumura, T.
    Arum, S.
    Hale, C.
    Jay, P. Y.
    Capocelli, K.
    Gonzalez-Duarte, A.
    EUROPEAN HEART JOURNAL, 2022, 43 : 2625 - 2625
  • [37] NEUROPATHY IMPAIRMENT AND NUTRITIONAL STATUS WITH EPLONTERSEN IN PATIENTS WITH HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS
    Conceicao, Isabel
    Wixner, Jonas
    Berk, John
    Adams, David
    Polydefkis, Michael
    Attarian, Shahram
    Gillmore, Julian
    Dyck, P. James
    Coelho, Teresa
    Chen, Jersey
    Hardy, Elise
    Kwoh, Jesse
    Natman, Jonatan
    Cruz, Marcia Waddington
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2024, 29 : S138 - S138
  • [38] Switching from inotersen to eplontersen in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: analysis from NEURO-TTRansform
    Conceicao, Isabel
    Berk, John L.
    Weiler, Markus
    Kowacs, Pedro A.
    Dasgupta, Noel R.
    Khella, Sami
    Chao, Chi-Chao
    Attarian, Shahram
    Kwoh, T. Jesse
    Jung, Shiangtung W.
    Chen, Jersey
    Viney, Nicholas J.
    Yu, Rosie Z.
    Gertz, Morie
    Masri, Ahmad
    Cruz, Marcia Waddington
    Coelho, Teresa
    JOURNAL OF NEUROLOGY, 2024, 271 (10) : 6655 - 6666
  • [39] COST OF INOTERSEN AND PATISIRAN FOR THE TREATMENT OF ADULTS WITH POLYNEUROPATHY OF HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS IN CANADA, GERMANY, AND ITALY
    Brown, D.
    Vera-Llonch, M.
    Shaff, M.
    Rolli, A.
    Vega, M.
    Blum, M.
    Nestler-Parr, S.
    Jiresch, M.
    Weycker, D.
    VALUE IN HEALTH, 2020, 23 : S606 - S607
  • [40] Correction to: Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR)
    Daniel P. Judge
    Arnt V. Kristen
    Martha Grogan
    Mathew S. Maurer
    Rodney H. Falk
    Mazen Hanna
    Julian Gillmore
    Pushkal Garg
    Akshay K. Vaishnaw
    Jamie Harrop
    Christine Powell
    Verena Karsten
    Xiaoping Zhang
    Marianne T. Sweetser
    John Vest
    Philip N. Hawkins
    Cardiovascular Drugs and Therapy, 2020, 34 : 889 - 889
12345